Osteoporosis: challenges and new opportunities for therapy.
Osteoporosis is a chronic disease that affects a large number of both men and women and is characterized by a decrease in bone mass, as well as weakened bones. It causes a significant amount of morbidity and mortality in patients and is often only diagnosed after a fracture occurs. This review will highlight recent advances in the development of novel anabolic approaches for treatment of osteoporosis, such as parathyroid hormone (PTH), calcium sensing receptor modulators, statins and prostanoid receptor agonists. Selected antiresorptive targets (cathepsin K inhibitors and vitronectin receptor antagonists) will also be surveyed.
Rotella
David P
DP
Hopewell Discovery Chemistry, Bristol-Myers Squibb Company, PO Box 5400, Princeton, NJ 08543 5400, USA. david.rotella@bms.com
D000818:Animals; D002986:Clinical Trials as Topic / Q000639:trends; D004164:Diphosphonates / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000379:methods; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage / Q000737:chemistry; D007093:Imidazoles / Q000008:administration & dosage / Q000737:chemistry; D010024:Osteoporosis / Q000178:diet therapy / Q000188:drug therapy* / Q000503:physiopathology; D010281:Parathyroid Hormone / Q000008:administration & dosage / Q000737:chemistry; D010446:Peptide Fragments / Q000008:administration & dosage / Q000737:chemistry; D000077211:Zoledronic Acid
D004164:Diphosphonates; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007093:Imidazoles; D010281:Parathyroid Hormone; D010446:Peptide Fragments; D000077211:Zoledronic Acid